Alpidem

Last updated

Alpidem
Alpidem.svg
Clinical data
Trade names Ananxyl
Other namesSL 80.0342; SL800342; SL-800342
Routes of
administration 		Oral administration
Drug class Nonbenzodiazepine; GABAA receptor positive allosteric modulator; Anxiolytic
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 32–35% (estimated) [1] [2]
Protein binding 99.4% [1]
Metabolism Extensive (hydroxylation, dealkylation, conjugation) [1]
Metabolites Many (some active) [1]
Onset of action 1.0–2.5 hours (Cmax) [1]
Elimination half-life Young adults: 19 hours (7–44 hours) [1]
Elderly: 22.6 ± 2.3 hours [1]
Children: 11.4 ± 1.9 hours [1]
Excretion Mainly feces [1]
Identifiers
  • 2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.216.305 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C21H23Cl2N3O
Molar mass 404.34 g·mol−1
3D model (JSmol)
  • CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
  • InChI=1S/C21H23Cl2N3O/c1-3-11-25(12-4-2)20(27)13-18-21(15-5-7-16(22)8-6-15)24-19-10-9-17(23)14-26(18)19/h5-10,14H,3-4,11-13H2,1-2H3 Yes check.svgY
  • Key:JRTIDHTUMYMPRU-UHFFFAOYSA-N Yes check.svgY
   (verify)

Alpidem, sold under the brand name Ananxyl, is a nonbenzodiazepine anxiolytic medication which was briefly used to treat anxiety disorders but is no longer marketed. [3] It was previously marketed in France, but was discontinued due to liver toxicity. [3] Alpidem is taken by mouth. [1]

Contents

Side effects of alpidem include sedation, fatigue, dizziness, and headache, among others. [3] [2] [4] It has much less to no impact on cognition, memory, and psychomotor function relative to benzodiazepines. [3] [5] Similarly, no rebound anxiety or withdrawal symptoms have been observed with alpidem. [3] [2] Rarely, alpidem can cause serious liver toxicity, including liver failure and death. [3] Alpidem is a nonbenzodiazepine of the imidazopyridine family, structurally related to the Z-drug zolpidem, [1] and acts as a GABAA receptor positive allosteric modulator of the benzodiazepine site of the receptor complex. [3] In contrast to zolpidem however, alpidem has anxiolytic effects rather than sedative or hypnotic effects at normal therapeutic doses. [3]

Alpidem was first described by 1982 [6] [7] and was introduced for medical use in France in 1991. [3] [8] [9] It was also under development for use in other countries in the 1990s, but development was discontinued and the drug was never marketed in any other country. [8] [9] Alpidem was withdrawn from the market in France in 1993 due to liver toxicity. [10] [11] [12] [13] [3]

Medical uses

Alpidem was approved for the treatment of generalized anxiety disorder and possibly also other anxiety problems. [3] [14] [8] By 1990, 17 clinical studies including more than 1,500 patients had been conducted in Europe studying alpidem for the treatment of anxiety. [2] [3] In clinical trials, alpidem demonstrated effectiveness in the treatment of chronic and situational anxiety, including stress-related anxiety, generalized anxiety, and adjustment disorder (situational depression) with anxiety. [2] [14] It also showed preliminary effectiveness in institutionalized individuals with chronic psychosis and high anxiety levels. [2] [15] The effectiveness of alpidem for panic disorder, on the other hand, is understudied and uncertain. [14] [16]

The anxiolytic effects of alpidem are described as rapid, robust, and maintained in the long-term. [3] [2] For situational anxiety, the anxiolytic effects of alpidem onset within 1.5 to 2 hours, whereas for chronic anxiety disorders the effects onset within 3 to 5 days in most cases. [2] No indications of tolerance to its anxiolytic effects or need for dose increases have been observed. [2] In people with anxiety taking alpidem, improvement in mood and sleep have also been found. [4]

The anxiolytic effectiveness of alpidem, for example measured by reductions on the Hamilton Anxiety Rating Scale (HAM-A), was superior to placebo and comparable or equivalent to that of benzodiazepines including diazepam (10–15 mg/day), lorazepam (1–6 mg/day), and clorazepate (30 mg/day) in directly comparative randomized controlled trials. [3] [2] [4] [14] Alpidem has also been directly compared with buspirone (20–30 mg/day) for generalized anxiety disorder. [17] Relative to buspirone, it was found to produce more rapid improvement, to have significantly greater effectiveness, and to have fewer side effects and a lower discontinuation rate. [17]

The recommended dose of alpidem was 75 to 150 mg total per day, given in single doses of 25 to 75 mg two to three times per day. [3] [18] [19]

Available forms

Alpidem was provided in the form of 50-mg oral tablets. [20]

Side effects

Alpidem is described as well-tolerated. [2] Side effects include sedation (6–8%; dose-dependent), fatigue (3–4%), dizziness (3–4%), and headache (2–3%), among others. [3] It is reported to have minimal sedative effects and to have virtually no negative effects on cognition, memory, and psychomotor function at therapeutic doses. [3] [2] [4] However, some impairment of vigilance and psychomotor function has been reported at high doses (100–200 mg). [3] [2] In addition, driving ability has been studied with alpidem and has been found to be impaired. [21] [22] The central side effects of alpidem were found to be no worse in elderly people than in young adults. [3] [23]

Alpidem does not alter sleep architecture as measured by electroencephalography. [2] In laboratory tests, 0.9% of patients treated with alpidem showed alterations. [2] No adverse effects on cardiovascular or respiratory function were seen in clinical trials. [2]

No rebound anxiety or withdrawal symptoms have been observed with alpidem after abrupt discontinuation following 4 weeks to 6–12 months of treatment. [3] [2] [4] Conversely, substantial withdrawal symptoms, including rebound anxiety, were observed with lorazepam. [4]

The side effects of alpidem are described as quite different from those of benzodiazepines. [3] In directly comparative trials, alpidem produced similar anxiolytic effects with less fatigue, asthenia, depressive mood, and psychomotor impairment than benzodiazepines, while rates of somnolence and drowsiness were comparable to benzodiazepines but described as milder in severity. [2] [4] Whereas benzodiazepines commonly produce dizziness, muscle weakness, fatigue, and sleepiness as side effects, these are not prominent adverse effects with doses of alpidem that have similar anxiolytic effectiveness. [3] The lack of withdrawal or rebound symptoms with alpidem upon discontinuation is also in contrast to benzodiazepines. [2] In addition, alpidem significantly antagonized the amnestic effects of lorazepam and showed similar trends for other cognitive measures in a clinical study in which the two drugs were combined and assessed for interaction. [3] [24]

Following marketing authorization in France, several cases of severe liver toxicity were reported in people taking alpidem. [3] [25] This resulted in one death and several cases of liver transplantation. [3] [25] [26] As a result, alpidem was soon withdrawn from the market. [3] The liver toxicity of alpidem was subsequently characterized in preclinical research. [27] [28] [29] [19] It may be related to interactions of alpidem with the translocator protein (TSPO), which is present in high amounts in the liver and which may mediate toxic effects in this tissue. [28] [29] [17] [19]

Overdose

Little information is available on overdose with alpidem. [2] Doses of as high as 300 mg/day, which is 2 to 4 times the recommended total daily dose, were assessed in clinical trials. [2] [3] [30]

Interactions

Alpidem may interact with alcohol, but to a lesser extent than benzodiazepines. [4]

Pharmacology

Pharmacodynamics

Alpidem is a GABAA receptor positive allosteric modulator (GABAkine), [31] specifically acting as an agonist of the benzodiazepine site of the receptor complex (formerly known as the central benzodiazepine receptor (CBR)). [3] In addition to its affinity for the benzodiazepine site of the GABAA receptor (Ki = 1–28 nM), alpidem has similarly high affinity for the translocator protein (TSPO) (formerly the peripheral benzodiazepine receptor (PBR)) (Ki = 0.5–7 nM). [32] [33] [34] [35] [36] Alpidem shows more than 500-fold selectivity for α1 subunit-containing GABAA receptors over α5 subunit-containing GABAA receptors [3] and 80-fold selectivity for α1 subunit-containing GABAA receptors over α3 subunit-containing GABAA receptors. [37] However, alpidem has also been described as potently modulating α1, α2, and α3 subunit-containing GABAA receptors with no effect on α5 subunit-containing GABAA receptors. [38] Findings appear to be mixed on whether alpidem is a partial agonist or a full agonist of the benzodiazepine site of the GABAA receptor. [3] In animals, alpidem has anxiolytic-like effects in some but not all models, weak anticonvulsant effects, and weak or no sedative, amnesic, ataxic, or muscle relaxant effects. [3] [5] [39] [30] High doses of alpidem antagonize the sedative and muscle relaxant effects of diazepam in animals. [39] Flumazenil has been shown to antagonize the anxiolytic and anticonvulsant effects of alpidem in animals. [5] Besides acting directly via the GABAA receptor, interactions with the TSPO might also contribute to the anxiolytic effects of alpidem. [40] [32] [41] [38] This protein mediates promotion of neurosteroidogenesis in the brain, for instance of allopregnanolone. [40] [32] [41]

Alpidem is structurally related to zolpidem, and both alpidem and zolpidem are GABAA receptor positive allosteric modulators of the benzodiazepine site with preference for α1 subunit-containing receptors. [3] [14] Both alpidem and zolpidem have very low affinity for α5 subunit-containing GABAA receptors, in contrast to benzodiazepines. [42] [43] Similarly, both alpidem and zolpidem are selective for γ2 subunit-containing GABAA receptors, with very low affinity for γ1 and γ3 subunit-containing GABAA receptors, in contrast to other Z-drugs and to diazepam. [44] Alpidem has very high affinity for the TSPO, while zolpidem has very low affinity for this protein. [14] [45] [46] The affinity of alpidem for the TSPO (also previously known as the ω3 receptor) [47] was once the highest of any drug known. [45] Although benzodiazepines like diazepam are also known to bind to the TSPO, the affinity of alpidem for this protein is at least 3,000-fold higher in comparison. [45] Whereas zolpidem shows hypnotic and sedative effects and is used to treat insomnia, alpidem shows mainly anxiolytic effects and is used to treat anxiety disorders. [3] [14] Alpidem was developed before the widespread use of recombinant GABAA receptors. [3] Hence, its pharmacological profile at the GABAA receptors, including its profile at different subpopulations of these receptors, has never been fully characterized. [3]

The pharmacodynamic mechanisms underlying the anxioselective (anxiolytic-selective) profile of alpidem as a GABAA receptor positive allosteric modulator are unclear. [3] [48] In any case, subtype selectivity for different populations of GABAA receptors, partial agonism of the benzodiazepine site of the GABAA receptor, and/or interactions with the TSPO may potentially all be involved. [3] [45] [5] [49] [39] [50] [51] Although anxioselective profiles have been observed for many GABAA receptor positive allosteric modulators in preclinical research, alpidem is the only GABAA receptor positive allosteric modulator for which anxioselective effects have been unambiguously demonstrated in human clinical trials. [3] Ocinaplon has also shown preliminary signs of an anxioselective profile in clinical studies, but development of this agent was discontinued in late-stage trials due to findings of elevated liver enzymes in a small subset of patients. [3] GABAA receptor positive allosteric modulators with selectivity for α2 and α3 subunit-containing GABAA receptors over α1 subunit-containing GABAA receptors, for instance adipiplon, L-838,417, and darigabat—among others, have been and are under investigation as potential anxioselective agents. [3] [31] [52] However, no such drugs have yet completed clinical development or been marketed for medical use. [31] [52] [48] [38] Despite many developmental failures, alpidem serves as a potential proof of concept that anxioselective GABAA receptor positive allosteric modulators may be possible. [3] [48] [38] However, if interactions with the TSPO are key to the anxiolytic effects of alpidem, then this may not actually be the case. [41]

Pharmacokinetics

Absorption

Alpidem is taken via oral administration. [1] The absorption of alpidem is rapid and it reaches peak levels after 1.0 to 2.5 hours. [1] Its overall bioavailability is estimated to be approximately 32 to 35%, but no precise value for absolute bioavailability has been determined. [1] [2] Absorption of alpidem as indicated by peak and area-under-the-curve levels is linear across a dose range of 25 to 100 mg. [1] Food increases the bioavailability of alpidem by 15 to 20%. [1]

Distribution

Alpidem is a highly lipophilic compound and in animals is extensively distributed into lipid-rich tissues. [1] Similarly, alpidem has been shown to cross the blood–brain barrier in animals, and showed a brain/plasma ratio of about 2.0 to 2.5 following systemic administration. [1] This is related to significantly slower efflux of alpidem from the brain than entry. [1] The active metabolites of alpidem are also brain-penetrant, although occur in the brain at levels lower than those of alpidem. [1] Alpidem may be concentrated more in lipid-rich white matter brain structures than grey matter structures. [1] In humans, the volume of distribution of alpidem is large at 8.7 L•kg−1. [1] The plasma protein binding of alpidem is 99.4%, with similar isolated fractions bound to albumin (97.0%) and α1-acid glycoprotein (97.3%). [1] The free fraction of alpidem is slightly higher in people with cirrhosis (0.86 ± 0.06%) and renal failure (0.72 ± 0.03%) relative to normal individuals (0.61 ± 0.05%). [1]

Metabolism

Alpidem is extensively metabolized, including by hydroxylation, dealkylation, and conjugation. [1] Many metabolites of alpidem have been identified, and some of these metabolites may contribute to its pharmacological activity. [1]

Elimination

Alpidem is eliminated mainly in feces, with less than 0.1% excreted in urine. [1] A majority of alpidem is eliminated within 48 to 72 hours following oral dosing. [1] Only trace amounts of unchanged alpidem are found in feces and urine. [1] The metabolites of alpidem are excreted mainly in via the bile in feces, with less than 5% eliminated via urine. [1]

The elimination half-life of alpidem was mean 18.8 ± 0.8 hours (range 7 to 44 hours) following a single 50-mg oral dose given to young individuals. [1] In elderly individuals, a trend toward a longer half-life was observed (22.6 ± 2.3 hours). [1] Conversely, in children age 8 to 12 years, the half-life of alpidem was considerably reduced (11.4 ± 1.9 hours). [1] The half-lives of alpidem and its metabolites are significantly prolonged in people with hepatic impairment. [1] Conversely, the half-lives of alpidem and its metabolites were unchanged in people with different stages of renal impairment, though plasma concentrations were significantly increased. [1] The clearance of alpidem was estimated to be 0.86 ± 0.04 L•h−1•kg−1 in healthy individuals. [1]

Chemistry

Alpidem is a nonbenzodiazepine, and hence is not structurally related to benzodiazepines. [1] [53] It is a member of the imidazopyridine group of compounds. [1] [14] Alpidem is structurally related to the Z-drug zolpidem, which is also an imidazopyridine. [1] [14]

History

Alpidem was developed by Synthélabo Recherche (subsequently Sanofi-Synthélabo and now Sanofi-Aventis). [4] [9] It was developed under the code name SL 80.0342 and was first described in the literature by 1982. [54] [6] [7] [8] Alpidem was introduced for medical use in France in 1991. [3] [8] [9] It was also undergoing development in the 1990s for use in other countries such as the United States and other European countries like Germany, the Netherlands, and Spain. [8] The drug reached phase 3 clinical trials in these countries. [8] However, development in the United States was halted in 1992 due to "divergent results". [55] [8] All development in other countries was discontinued by 1999. [8] Alpidem was withdrawn from the market in France in 1993 due to liver toxicity. [10] [11] [12] [13] [3] It was never marketed in any other country. [8] [54] [9]

Society and culture

Names

Alpidem is the generic name of the drug and its INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name, BAN Tooltip British Approved Name, and DCF Tooltip Dénomination Commune Française. [6] [54] The developmental code name of alpidem was SL 80.0342. [54] [8] Alpidem was previously marketed under the brand name Ananxyl. [6] [54]

Availability

Alpidem was previously marketed in France, but is no longer available in any country. [3] [8] [9]

See also

Related Research Articles

<span class="mw-page-title-main">Zolpidem</span> Hypnotic medication

Zolpidem, sold under the brand name Ambien among others, is a medication primarily used for the short-term treatment of sleeping problems. Guidelines recommend that it be used only after cognitive behavioral therapy for insomnia and after behavioral changes, such as sleep hygiene, have been tried. It decreases the time to sleep onset by about fifteen minutes and at larger doses helps people stay asleep longer. It is taken by mouth and is available in conventional tablets, sublingual tablets, or oral spray.

<span class="mw-page-title-main">Imidazopyridine</span> Class of compounds

An imidazopyridine is a nitrogen containing heterocycle that is also a class of drugs that contain this same chemical substructure. In general, they are GABAA receptor agonists, however recently proton pump inhibitors, aromatase inhibitors, NSAIDs and other classes of drugs in this class have been developed as well. Despite usually being similar to them in effect, they are not chemically related to benzodiazepines. As such, GABAA-agonizing imidazopyridines, pyrazolopyrimidines, and cyclopyrrones are sometimes grouped together and referred to as "nonbenzodiazepines." Imidazopyridines include:

GABA<sub>A</sub> receptor Ionotropic receptor and ligand-gated ion channel

The GABAA receptor (GABAAR) is an ionotropic receptor and ligand-gated ion channel. Its endogenous ligand is γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Accurate regulation of GABAergic transmission through appropriate developmental processes, specificity to neural cell types, and responsiveness to activity is crucial for the proper functioning of nearly all aspects of the central nervous system (CNS). Upon opening, the GABAA receptor on the postsynaptic cell is selectively permeable to chloride ions and, to a lesser extent, bicarbonate ions.

<span class="mw-page-title-main">Nonbenzodiazepine</span> Class of psychoactive drugs

Nonbenzodiazepines, sometimes referred to colloquially as Z-drugs, are a class of psychoactive, depressant, sedative, hypnotic, anxiolytic drugs that are benzodiazepine-like in uses, such as for treating insomnia and anxiety.

<span class="mw-page-title-main">Quazepam</span> Benzodiazipine

Quazepam, sold under the brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s. Quazepam is used for the treatment of insomnia, including sleep induction and sleep maintenance. Quazepam induces impairment of motor function and has relatively selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines. Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.

<span class="mw-page-title-main">Neurosteroid</span> Compounds that affect neuronal excitability through modulation of specific ionotropic receptors

Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.

<span class="mw-page-title-main">Adinazolam</span> Triazolobenzodiazepine drug

Adinazolam is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed. Adinazolam was never FDA approved and never made available to the public market; however, it has been sold as a designer drug.

<span class="mw-page-title-main">Bretazenil</span> Chemical compound

Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug which is derived from the benzodiazepine family, and was invented in 1988. It is most closely related in structure to the GABA antagonist flumazenil, although its effects are somewhat different. It is classified as a high-potency benzodiazepine due to its high affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile. In particular bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5 and α6 subunit containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5GABAA benzodiazepine receptor complexes.

<span class="mw-page-title-main">Pagoclone</span> Chemical compound

Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. It was synthesized by a French team working for Rhone-Poulenc & Rorer S.A. Pagoclone belongs to the class of nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It was never commercialised.

<span class="mw-page-title-main">DMCM</span> Chemical compound

DMCM is a drug from the β-carboline family that induces anxiety and convulsions by acting as a negative allosteric modulator of GABAA receptors — functionally opposite to benzodiazepines and related drugs which are positive allosteric modulators — and is used in scientific research for these properties to test new anxiolytic and anticonvulsant medications, respectively. It has also been shown to produce analgesic effects in animals, which is thought to be the drug's induced panic reducing the perception of pain.

<span class="mw-page-title-main">Etifoxine</span> Anxiolytic medication

Etifoxine, sold under the trade name Stresam among others, is a nonbenzodiazepine anxiolytic agent, primarily indicated for short-term management of adjustment disorder, specifically instances of situational depression accompanied by anxiety, such as stress-induced anxiety. Administration is by mouth. Side effects associated with etifoxine use include slight drowsiness, headache, skin eruptions, and allergic reactions. In rare cases, etifoxine has been linked to severe skin and liver toxicity, as well as menstrual bleeding between periods. Unlike benzodiazepines, etifoxine does not cause sedation or lack of coordination. Etifoxine acts as a GABAA receptor positive allosteric modulator and as a ligand for translocator proteins. Both mechanisms are conjectured to contribute to its anxiolytic properties.

<span class="mw-page-title-main">Saripidem</span> Chemical compound

Saripidem is a sedative and anxiolytic drug in the imidazopyridine family, which is related to the better known drugs zolpidem and alpidem.

<span class="mw-page-title-main">Abecarnil</span> Chemical compound

Abecarnil (ZK-112,119) is an anxiolytic drug from the β-Carboline family. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It is a partial agonist acting selectively at the benzodiazepine site of the GABAA receptor.

<span class="mw-page-title-main">L-838,417</span> Chemical compound

L-838,417 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. The compound was developed by Merck, Sharp and Dohme.

<span class="mw-page-title-main">SL651498</span> Chemical compound

SL651498 is an anxiolytic and anticonvulsant drug used in scientific research, with a chemical structure most closely related to β-carboline derivatives such as abecarnil and gedocarnil. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

<span class="mw-page-title-main">CL-218,872</span> Chemical compound

CL-218,872 is a sedative and hypnotic drug used in scientific research. It has similar effects to sedative-hypnotic benzodiazepine drugs such as triazolam, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic.

<span class="mw-page-title-main">SX-3228</span> Chemical compound

SX-3228 is a sedative and hypnotic drug used in scientific research. It has similar effects to sedative-hypnotic benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic.

<span class="mw-page-title-main">CGS-20625</span> Chemical compound

CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects. It is orally active in humans, but with relatively low bioavailability.

<span class="mw-page-title-main">TPA-023</span> Chemical compound

TPA-023 (MK-0777) is an anxiolytic drug with a novel chemical structure, which is used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. It is a mixed, subtype-selective ligand of the benzodiazepine site of α1, α2, α3, and α5-containing GABAA receptors, where it acts as a partial agonist at benzodiazepine sites of the α2 and α3-containing subtypes, but as a silent antagonist at α1 and α5-containing subtypes. It has primarily anxiolytic and anticonvulsant effects in animal tests, but with no sedative effects even at 50 times the effective anxiolytic dose.

<span class="mw-page-title-main">DS-1 (drug)</span> Chemical compound

DS-1 is a drug from the imidazopyridine family, which is the first drug developed that acts as a GABAA receptor positive allosteric modulator (PAM) selective for the α4β3δ subtype, which is not targeted by other GABAA receptor PAMs such as the benzodiazepines or other nonbenzodiazepine drugs. Novel selective drugs such as DS-1 are useful in the study of this receptor subtype.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Durand A, Thénot JP, Bianchetti G, Morselli PL (1992). "Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem". Drug Metabolism Reviews. 24 (2): 239–266. doi:10.3109/03602539208996294. PMID   1576937.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Morselli PL (May 1990). "On the therapeutic action of alpidem in anxiety disorders: an overview of the European data". Pharmacopsychiatry. 23 (Suppl 3): 129–134. doi:10.1055/s-2007-1014549. PMID   1974073.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 Skolnick P (November 2012). "Anxioselective anxiolytics: on a quest for the Holy Grail". Trends in Pharmacological Sciences. 33 (11): 611–620. doi:10.1016/j.tips.2012.08.003. PMC   3482271 . PMID   22981367.
  4. 1 2 3 4 5 6 7 8 9 Morton S, Lader M (May 1990). "Studies with alpidem in normal volunteers and anxious patients". Pharmacopsychiatry. 23 (Suppl 3): 120–123. doi:10.1055/s-2007-1014547. PMID   1974071. S2CID   28795734.
  5. 1 2 3 4 Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (May 1990). "Pharmacological and behavioral profile of alpidem as an anxiolytic". Pharmacopsychiatry. 23 (Suppl 3): 108–113. doi:10.1055/s-2007-1014545. PMID   1974069. S2CID   41341117.
  6. 1 2 3 4 J. Elks, ed. (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 33–. ISBN   978-1-4757-2085-3. OCLC   1058412474.
  7. 1 2 Saletu B, Grünberger J, Linzmayer L (April 1986). "Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry". International Clinical Psychopharmacology. 1 (2): 145–164. doi:10.1097/00004850-198604000-00006. PMID   2883214.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 "Alpidem - Sanofi-Synthelabo - AdisInsight".
  9. 1 2 3 4 5 6 "Micromedex Products: Please Login".
  10. 1 2 Guengerich FP (2011). "Mechanisms of drug toxicity and relevance to pharmaceutical development". Drug Metabolism and Pharmacokinetics. 26 (1): 3–14. doi:10.2133/dmpk.dmpk-10-rv-062. PMC   4707670 . PMID   20978361.
  11. 1 2 "ANANXYL WITHDRAWN FROM MARKET IN FRANCE - Pharmaceutical industry news".
  12. 1 2 "La commercialisation de l'Ananxyl est suspendue pour un an". Le Monde.fr. 26 October 1993.
  13. 1 2 WHO Drug Information Vol. 8, No. 2, 1994, page 64
  14. 1 2 3 4 5 6 7 8 9 Kunovac JL, Stahl SM (December 1995). "Future directions in anxiolytic pharmacotherapy". The Psychiatric Clinics of North America. 18 (4): 895–909. doi:10.1016/S0193-953X(18)30030-3. PMID   8748388.
  15. ↑ Kishi T, Inada K, Matsui Y, Iwata N (October 2017). "Z-drug for schizophrenia: A systematic review and meta-analysis". Psychiatry Research. 256: 365–370. doi:10.1016/j.psychres.2017.06.063. PMID   28686934. S2CID   13656676.
  16. ↑ Schneier FR, Carrasco JL, Hollander E, Campeas R, Fallon B, Saoud JB, et al. (April 1993). "Alpidem in the treatment of panic disorder". Journal of Clinical Psychopharmacology. 13 (2): 150–153. doi:10.1097/00004714-199304000-00011. PMID   8096527.
  17. 1 2 3 Potokar J, Nutt DJ (April 1994). "Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists". CNS Drugs. 1 (4): 305–315. doi:10.2165/00023210-199401040-00007. ISSN   1172-7047. S2CID   71162271.
  18. ↑ Joris C. Verster, S. R. Pandi-Perumal, Jan G. Ramaekers, Johan J. de Gier, eds. (29 August 2009). Drugs, Driving and Traffic Safety. Springer Science & Business Media. pp. 301–. ISBN   978-3-7643-9923-8. OCLC   1005763473.
  19. 1 2 3 "NCATS Inxight Drugs — ALPIDEM".
  20. ↑ Mokrov GV, Deeva OA, Gudasheva TA (2021). "The Ligands of Translocator Protein: Design and Biological Properties". Current Pharmaceutical Design. 27 (2): 217–237. doi:10.2174/1381612826666200903122025. PMID   32881658. S2CID   221498255.
  21. ↑ Verster J, Veldhuijzen D, Volkerts E (1 June 2005). "Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from on-the-Road Driving Studies During Normal Traffic". Current Psychiatry Reviews. 1 (2): 215–225. doi:10.2174/1573400054065613. ISSN   1573-4005.
  22. ↑ Griffin CE, Kaye AM, Bueno FR, Kaye AD (2013). "Benzodiazepine pharmacology and central nervous system-mediated effects". The Ochsner Journal. 13 (2): 214–223. PMC   3684331 . PMID   23789008.
  23. ↑ Hindmarch I (May 1990). "Alpidem and psychological performance in elderly subjects". Pharmacopsychiatry. 23 (Suppl 3): 124–128. doi:10.1055/s-2007-1014548. PMID   1974072. S2CID   7987272.
  24. ↑ Patat A, Perault MC, Vandel B, Danjou P, Brohier S, Zieleniuk I, Rosenzweig P (January 1995). "Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers". Journal of Psychopharmacology. 9 (2): 91–101. doi:10.1177/026988119500900203. PMID   22298734. S2CID   25269937.
  25. 1 2 Baty V, Denis B, Goudot C, Bas V, Renkes P, Bigard MA, et al. (1994). "[Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]" [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]. Gastroenterologie Clinique et Biologique (in French). 18 (12): 1129–1131. PMID   7750686.
  26. ↑ Ausset P, Malavialle P, Vallet A, Miremont G, Le Bail B, Dumas F, et al. (February 1995). "[Subfulminant hepatitis caused by alpidem and treated by liver transplantation]" [Subfulminant hepatitis caused by alpidem and treated by liver transplantation]. Gastroenterologie Clinique et Biologique (in French). 19 (2): 222–223. PMID   7750714.
  27. ↑ Labbe G, Pessayre D, Fromenty B (August 2008). "Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies". Fundamental & Clinical Pharmacology. 22 (4): 335–353. doi:10.1111/j.1472-8206.2008.00608.x. PMID   18705745. S2CID   22969724.
  28. 1 2 Pessayre D, Mansouri A, Berson A, Fromenty B (2010). "Mitochondrial involvement in drug-induced liver injury". Adverse Drug Reactions. Handbook of Experimental Pharmacology. Vol. 196. pp. 311–365. doi:10.1007/978-3-642-00663-0_11. ISBN   978-3-642-00662-3. PMID   20020267.
  29. 1 2 Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, et al. (November 2001). "Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation". The Journal of Pharmacology and Experimental Therapeutics. 299 (2): 793–800. PMID   11602696.
  30. 1 2 Musch B, Morselli PL, Priore P (April 1988). "Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences". Pharmacology, Biochemistry, and Behavior. 29 (4): 803–806. doi:10.1016/0091-3057(88)90211-0. PMID   2901120. S2CID   42445239.
  31. 1 2 3 Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, et al. (June 2022). "GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacology & Therapeutics. 234: 108035. doi:10.1016/j.pharmthera.2021.108035. PMC   9787737 . PMID   34793859.
  32. 1 2 3 Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C (2009). "Translocator protein ligands as promising therapeutic tools for anxiety disorders". Current Medicinal Chemistry. 16 (26): 3359–3380. doi:10.2174/092986709789057653. PMID   19548867.
  33. ↑ Bourguignon JJ (1993). "Endogenous and Synthetic Ligand of Mitochondrial Benzodiazepine Receptors: Structure-Affinity Relationships.". In Giesen-Crouse E (ed.). Peripheral Benzodiazepine Receptors. London: Academic Press. pp. 59–85.
  34. ↑ Costa E, Romeo E, Auta J, Papadopoulos V, Kozikowski A, Guidotti A (1991). "Is There a Pharmacology of Brain Steroidogenesis? In Neurosteroid and Brain Function". In Costa E, Paul SM (eds.). Fidia ResearchFundation Symposium Series. New York: Thieme Medical Publisher, Inc. pp. 171–176.
  35. ↑ Romeo E, Auta J, Kozikowski AP, Ma D, Papadopoulos V, Puia G, et al. (September 1992). "2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR)". The Journal of Pharmacology and Experimental Therapeutics. 262 (3): 971–978. PMID   1326631.
  36. ↑ Kozikowski AP, Ma D, Romeo E, Auta J, Papadopoulos V, Puia G, Costa E, Guidotti A (August 1992). "Synthesis of (2-Arylindol-3-yl) acetamides as Probes of Mitochondrial Steroidogenesis—A New Mechanism for GABAA Receptor Modulation". Angewandte Chemie International Edition in English. 31 (8): 1060–2. doi:10.1002/anie.199210601.
  37. ↑ Zivkovic B, Arbilla S, Perrault G, Sanger DJ, Langer SZ (September 1991). "Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment". European Neuropsychopharmacology. 1 (3): 202–205. doi:10.1016/0924-977X(91)90485-D. ISSN   0924-977X. S2CID   54414875.
  38. 1 2 3 4 Sieghart W, Savić MM (October 2018). "International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans". Pharmacological Reviews. 70 (4): 836–878. doi: 10.1124/pr.117.014449 . PMID   30275042. S2CID   52895644.
  39. 1 2 3 Haefely W, Martin JR, Schoch P (November 1990). "Novel anxiolytics that act as partial agonists at benzodiazepine receptors". Trends in Pharmacological Sciences. 11 (11): 452–456. doi:10.1016/0165-6147(90)90126-s. PMID   1980040.
  40. 1 2 Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R (January 2012). "Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile". Journal of Neuroendocrinology. 24 (1): 82–92. doi:10.1111/j.1365-2826.2011.02166.x. PMID   21609361. S2CID   21476596.
  41. 1 2 3 Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. (December 2010). "Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders". Nature Reviews. Drug Discovery. 9 (12): 971–988. doi:10.1038/nrd3295. PMID   21119734. S2CID   23296183.
  42. ↑ Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994). "Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes". Neuroscience and Biobehavioral Reviews. 18 (3): 355–372. doi:10.1016/0149-7634(94)90049-3. PMID   7984354. S2CID   11612995.
  43. ↑ Langer SZ, Faure-Halley C, Seeburg P, Graham D, Arbilla S (September 1992). "The selectivity of zolpidem and alpidem for the α1-subunit of the GABAA receptor". European Neuropsychopharmacology. 2 (3): 232–234. doi:10.1016/0924-977X(92)90081-I. ISSN   0924-977X. S2CID   140210499.
  44. ↑ Richter G, Liao VW, Ahring PK, Chebib M (2020). "The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABA A Receptors Containing γ1, γ2, and γ3 Subunits". Frontiers in Neuroscience. 14: 599812. doi: 10.3389/fnins.2020.599812 . PMC   7710685 . PMID   33328871.
  45. 1 2 3 4 Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE (May 1990). "Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs". Pharmacopsychiatry. 23 (Suppl 3): 103–107. doi:10.1055/s-2007-1014544. PMID   1974068. S2CID   46448714.
  46. ↑ Pleuvry BJ (August 2004). "Anxiolytics and hypnotics". Anaesthesia & Intensive Care Medicine. 5 (8): 252–256. doi:10.1383/anes.5.8.252.43294. ISSN   1472-0299.
  47. ↑ Guilarte TR (February 2019). "TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward". Pharmacology & Therapeutics. 194: 44–58. doi:10.1016/j.pharmthera.2018.09.003. PMC   6348013 . PMID   30189290.
  48. 1 2 3 Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, et al. (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology, Biochemistry, and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID   35041859. S2CID   245963990.
  49. ↑ Langer SZ, Arbilla S, Benavides J, Scatton B (1990). "Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes". Advances in Biochemical Psychopharmacology. 46: 61–72. PMID   1981304.
  50. ↑ Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991). "Animal models of anxiety and the development of novel anxiolytic drugs". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 15 (2): 205–212. doi:10.1016/0278-5846(91)90082-c. PMID   1678541. S2CID   36709046.
  51. ↑ Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (December 2000). "Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands". Psychopharmacology. 153 (1): 67–84. doi:10.1007/s002130000567. PMID   11255930. S2CID   1171230.
  52. 1 2 Quagliato LA, Carta MG, Nardi AE (2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID   36099401. S2CID   252219658.
  53. ↑ Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL (1991). "A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety". Psychopharmacology Bulletin. 27 (1): 67–71. PMID   1677774.
  54. 1 2 3 4 5 Swiss Pharmaceutical Society (2000). Swiss Pharmaceutical Society (ed.). Index Nominum 2000: International Drug Directory. Taylor & Francis. pp. 31–. ISBN   978-3-88763-075-1.
  55. ↑ "US TRIALS OF ALPIDEM HALTED - Pharmaceutical industry news".

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.